SMARCB1 monoclonal antibody (M02), clone 3E3
- Known as:
- SMARCB1 mab (anti-) (M02), clonality 3E3
- Catalog number:
- H00006598-M02
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Abno
- Gene target:
- SMARCB1 monoclonal antibody (M02) clone 3E3
Related genes to: SMARCB1 monoclonal antibody (M02), clone 3E3
- Gene:
- EMC10 NIH gene
- Name:
- ER membrane protein complex subunit 10
- Previous symbol:
- C19orf63
- Synonyms:
- INM02, HSS1, HSM1
- Chromosome:
- 19q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 2007-07-17
- Date modifiied:
- 2016-12-01
- Gene:
- MRPL1 NIH gene
- Name:
- mitochondrial ribosomal protein L1
- Previous symbol:
- -
- Synonyms:
- BM022
- Chromosome:
- 4q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-02-28
- Date modifiied:
- 2015-08-25
- Gene:
- PMS2 NIH gene
- Name:
- PMS1 homolog 2, mismatch repair system component
- Previous symbol:
- PMSL2
- Synonyms:
- H_DJ0042M02.9, HNPCC4, MLH4
- Chromosome:
- 7p22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-13
- Date modifiied:
- 2019-04-23
- Gene:
- SESN2 NIH gene
- Name:
- sestrin 2
- Previous symbol:
- -
- Synonyms:
- SES2, DKFZp761M0212, HI95, SEST2
- Chromosome:
- 1p35.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-03
- Date modifiied:
- 2016-10-05
- Gene:
- SMARCB1 NIH gene
- Name:
- SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
- Previous symbol:
- SNF5L1
- Synonyms:
- BAF47, Ini1, Snr1, hSNFS, Sfh1p, RDT, PPP1R144, SNF5
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-21
- Date modifiied:
- 2019-04-23
Related products to: SMARCB1 monoclonal antibody (M02), clone 3E3
Related articles to: SMARCB1 monoclonal antibody (M02), clone 3E3
- Atypical teratoid rhabdoid tumor (ATRT) is the most common malignant brain tumor in infants. ATRT is associated with inactivation/deletion of SMARCB1, a member of the SWI/SNF chromatin remodeling complex. SMARCB1 loss contributes to tumorigenicity by compromising SWI/SNF activity at specific loci associated with the CoREST repressor complex, which regulates transcription at critical gene promoters and enhancers. We therefore explored the role of the CoREST repressor complex in ATRT. - Source: PubMed
Publication date: 2026/07/21
Geethadevi AnupaVaidya NikhilFisher Robert JFindlay Tyler RDeng YimingPham KhoaKumar VikasBeck SamuelChoe JunLiu ShiyuLucas Calixto-Hope GEberhart Charles GXu JinchongCole Philip ARubens JeffreyCollard MarianneRaabe Eric HAlani Rhoda M - Desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant (DMT-SMARCB1) is a rare central nervous system neoplasm, with only approximately 15 reported cases. Published cases suggest a relatively indolent clinical course with low proliferative activity and no radiologically documented disseminated disease. We report a 47-year-old woman with a pineal region mass who developed aggressive recurrence and focal leptomeningeal dissemination following ventriculoperitoneal shunt placement and Gamma Knife radiosurgery. Histologically, the tumor was composed of discohesive rhabdoid cells embedded within a prominent myxoid stroma and focal collagenous matrix. Immunohistochemistry demonstrated loss of INI1 expression. DNA methylation profiling, interpreted in conjunction with histopathological and immunohistochemical findings, supported the diagnosis of DMT-SMARCB1 and demonstrated molecular proximity to other SMARCB1-deficient central nervous system neoplasms. Literature review revealed no previous reports of radiologically documented leptomeningeal dissemination. This case expands the clinicopathologic spectrum of DMT-SMARCB1 and highlights the potential for aggressive biological behavior despite relatively low-grade histologic features. - Source: PubMed
Publication date: 2026/07/17
Chang Yu-WeiLi Yao-FengChen Yun-AnWang Ren-ChingChang Nien-YiLiao Che-Chi - - Source: PubMed
Publication date: 2026/07/06
Tauziède-Espariat ArnaultDuchesne MathildeRouchaud AymericNegrier Amandine ChabernaudCoudert RomainBenzakoun JosephGuyon DavidSassi FarahHasty LaurenMétais AliceVarlet Pascale - Current World Health Organization (WHO) Classification of Urinary and Male Genital Tumours (2022) has introduced minor updates in the classification of renal cell carcinomas (RCC). Among the most notable changes is the recognition of a new category: molecularly defined RCC. This group comprises several distinct tumour entities characterized by specific genetic alterations. The inclusion of this category reflects the growing importance of molecular testing in the diagnosis, prognosis and treatment planning of renal malignancies. This review summarizes the basic information, clinical data, and treatment options of these rare RCCs. Due to the low prevalence of molecularly defined RCCs, the clinical management remains challenging, and standardized, evidence-based treatment guidelines are still lacking, particularly for the systemic therapy of advanced RCCs. As part of the review, a clinical case of a female patient with metastatic -translocated RCC is also presented, illustrating the diagnostic and therapeutic challenges. - Source: PubMed
Publication date: 2026/07/01
Stránský PetrKolář JiříŠiková DominikaPitra TomášPernický JanFiala OndřejPivovarčíková KristýnaOndič OndrejHora Milan - Epithelioid sarcoma is an exceedingly rare malignant soft tissue neoplasm with unclear histogenesis and distinctive epithelioid morphology. Primary epithelioid sarcoma of orbit represents an extremely rare clinical entity, with only isolated case reports documented globally. Notably, no formal, peer-reviewed case report of primary epithelioid sarcoma of orbit has been published in Asia to date. - Source: PubMed
Publication date: 2026/06/26
Yang GuangYuan JingpingChen FangfangYan HonglinLiu Wen